{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:16:05Z","timestamp":1781327765596,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12149-019-01378-1","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T11:02:32Z","timestamp":1560855752000},"page":"697-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Limited role of carbidopa-assisted 18F-FDOPA PET\/CT in patients with sporadic non-functional gastroduodenal neuroendocrine neoplasms"],"prefix":"10.1007","volume":"33","author":[{"given":"Alessio","family":"Imperiale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlinde","family":"Averous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Helali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Pessaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Goichot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bachellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"1378_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-3-319-40618-3_29","volume-title":"AJCC cancer staging manual","author":"EA Woltering","year":"2017","unstructured":"Woltering EA, Bergsland EK, Beyer DT. Neuroendocrine tumors of the stomach: American Joint Committee on Cancer 2017. In: Amin MB, editor. AJCC cancer staging manual. 8th ed. New York: Springer; 2017. p. 351\u20139.","edition":"8"},{"key":"1378_CR2","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.3748\/wjg.v22.i30.6817","volume":"22","author":"Y Sato","year":"2016","unstructured":"Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22:6817\u201328.","journal-title":"World J Gastroenterol"},{"key":"1378_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000335595","volume":"95","author":"G Delle Fave","year":"2012","unstructured":"Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95:74\u201387.","journal-title":"Neuroendocrinology"},{"key":"1378_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000443168","volume":"103","author":"G Delle-Fave","year":"2016","unstructured":"Delle-Fave G, O\u2019Toole D, Sundin A, Taal B, Ferolla P, Ramageet JK, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:119\u201324.","journal-title":"Neuroendocrinology"},{"key":"1378_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.soc.2015.08.010","volume":"25","author":"HA Farley","year":"2016","unstructured":"Farley HA, Pommier RF. Treatment of neuroendocrine liver metastases. Surg Oncol Clin N Am. 2016;25:217\u201325.","journal-title":"Surg Oncol Clin N Am"},{"key":"1378_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.bpg.2013.01.002","volume":"26","author":"D O\u2019Toole","year":"2012","unstructured":"O\u2019Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:719\u201335.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1378_CR7","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1245\/s10434-018-6673-5","volume":"25","author":"S Massironi","year":"2018","unstructured":"Massironi S, Campana D, Partelli S, Panzuto F, Rossi RE, Faggiano A, et al. Heterogeneity of duodenal neuroendocrine tumors: an italian multi-center experience. Ann Surg Oncol. 2018;25:3200\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1378_CR8","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2967\/jnumed.116.179234","volume":"57","author":"C Deerose","year":"2016","unstructured":"Deerose C, Hindie E, Kebebew E, Goichot B, Pacak K, Taieb D, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949\u201356.","journal-title":"J Nucl Med"},{"key":"1378_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00259-013-2342-x","volume":"40","author":"S Balogova","year":"2013","unstructured":"Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013;40:943\u201366.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1378_CR10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1210\/jc.2008-1349","volume":"94","author":"F Montravers","year":"2009","unstructured":"Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab. 2009;94:1295\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"key":"1378_CR11","first-page":"1455","volume":"47","author":"F Montravers","year":"2006","unstructured":"Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumours? J Nucl Med. 2006;47:1455\u201362.","journal-title":"J Nucl Med"},{"key":"1378_CR12","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","volume":"35","author":"V Ambrosini","year":"2008","unstructured":"Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1378_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","volume":"36","author":"A Haug","year":"2009","unstructured":"Haug A, Auernhammer CJ, W\u00e4ngler B, Tiling R, Schmidt G, G\u00f6ke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1378_CR14","first-page":"68","volume":"54","author":"D Putzer","year":"2010","unstructured":"Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging. 2010;54:68\u201375.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"1378_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2967\/jnumed.107.045708","volume":"49","author":"PL Jager","year":"2008","unstructured":"Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573\u201386.","journal-title":"J Nucl Med"},{"key":"1378_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S1470-2045(06)70801-4","volume":"7","author":"KP Koopmans","year":"2006","unstructured":"Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, et al. Staging of carcinoid tumours with 18FDOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728\u201334.","journal-title":"Lancet Oncol."},{"key":"1378_CR17","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00259-011-1862-5","volume":"38","author":"HB Fiebrich","year":"2011","unstructured":"Fiebrich HB, de Jong JR, Kema IP, Koopmans KP, Sluiter W, Dierckx RA, et al. Total (18)F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging. 2011;38:1854\u201361.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1378_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2967\/jnumed.113.126896","volume":"55","author":"A Imperiale","year":"2014","unstructured":"Imperiale A, Rust E, Gabriel S, Detour J, Goichot B, Duclos B, et al. 18F-fluorodihydroxyphenylalanine PET\/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J Nucl Med. 2014;55:367\u201372.","journal-title":"J Nucl Med"},{"key":"1378_CR19","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1200\/JCO.2008.18.8581","volume":"26","author":"S Kauhanen","year":"2008","unstructured":"Kauhanen S, Sepp\u00e4nen M, Nuutila P. Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [18F]-dihydroxy-phenyl-alanine positron emission tomography. J Clin Oncol. 2008;26:5307\u20138.","journal-title":"J Clin Oncol"},{"key":"1378_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00259-018-4245-3","volume":"46","author":"B Leroy-Freschini","year":"2019","unstructured":"Leroy-Freschini B, Amodru V, Addeo P, Sebag F, Vix M, Brunaud L, et al. Early\u00a018F-FDOPA PET\/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma. Eur J Nucl Med Mol Imaging. 2019;46:686\u201395.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1378_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/MNM.0b013e3283543304","volume":"33","author":"M Soussan","year":"2012","unstructured":"Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, et al. Added value of early 18F-FDOPA PET\/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33:775\u20139.","journal-title":"Nucl Med Commun"},{"key":"1378_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12149-016-1110-y","volume":"30","author":"M Helali","year":"2016","unstructured":"Helali M, Addeo P, Heimburger C, Detour J, Goichot B, Bachellier P, et al. Carbidopa-assisted 18F-fluorodihydroxyphenylalanine PET\/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors. Ann Nucl Med. 2016;30:659\u201368.","journal-title":"Ann Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-019-01378-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T23:20:52Z","timestamp":1592090452000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-019-01378-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s12149-019-01378-1","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]},"assertion":[{"value":"11 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors (AI, GA, MH, DT, PP, BG, PA, PB) declare that they have no conflict of interest in the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No institutional approval was required for retrospective studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}